Target Definitionoforbital Embryonal Rhabdomyosarcoma (Rms) by Multimodality Imaging: An Original Article

Although rhabdomyosarcoma (RMS) is a rare tumor among group of mesenchymal malignancies as a whole, orbital RMS constitutes the most frequent soft tissue sarcoma in the head and neck region in children [1-3]. Tissue of origin is the pluripotent mesenchyme, and the prognosis may be rather favorable, however, orbital embryonal RMS may pose a formidable challenge to the ocular oncologist in terms of diagnosis and management [1-3]. Affected patients may typically present with a rapidly enlarging mass frequuently localized in the upper inner quadrant. While pain is not a typical symptom, proptosis and diplopia may occur. Also, edema may result from invasion of the eyelid. Majority of orbital RMS are of the embryonal subtype occuring in the first decade of life. Treatments strategies for orbital embryonal RMS may include surgery, radiation therapy (RT), and chemotherapy. Satisfactory survival outcomes may be achieved for orbital embryonal RMS by use of these therapies, however, adverse effects of administered treatments are major concerns regarding management given the long life expectancy of affected patients. Within this context, improving the toxicity profile of treatment has been a critical aspect of management. In terms of RT, contemporary techniques and proton therapy have been utilized for improving the therapeutic ratio [4-7]. In this original article, we evaluated target definition for orbital embryonal RMS with multimodality imaging.